Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children

Objective:Understanding the extent to which early antiretroviral therapy (ART) can limit the establishment and persistence of the HIV reservoir is an important step to designing interventions aimed at achieving HIV cure. We measured the markers of HIV persistence and HIV-specific immunity in early treated children. Design:This is a cross-sectional study that enrolled 15 children older than 2 years of age who initiated ART before 6 months of age and had sustained viral suppression. Total and integrated HIV DNA, and 2-LTR circles in CD4+ T cells, HIV antibody response by fourth generation HIV enzyme immunoassay, and CD4+ and CD8+ T-cell responses to gag/env peptides by intracellular cytokine staining of CD4+ and CD8+ T cells were measured. Results:The median current age was 6.3 years and age at ART initiation was 17 weeks. The median duration of viral suppression was 6 years, and all had HIV RNA less than 50 copies/ml. The median CD4+ T cells was 44%. The median total HIV DNA was 132 copies/106 CD4+ T cells (range 11–1804) and integrated HIV DNA was 17 copies/106 CD4+ T cells (range 0–516), and no one had detectable 2-LTR circles. Nine of the 15 children (60%) had undetectable or extremely low integrated HIV DNA (<20 copies/106 CD4+ T cells). All except one (93%) had undetectable HIV-specific CD4+/CD8+ cell responses and seven (47%) had nonreactive enzyme immunoassay. Conclusion:Early ART resulted in very low levels of markers of HIV persistence and undetectable HIV-specific immune responses in the majority of HIV-infected children who started ART before 6 months of age.

[1]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[2]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[3]  Jerome H. Kim,et al.  A novel acute HIV infection staging system based on 4th generation immunoassay , 2013, Retrovirology.

[4]  C. Grady,et al.  Ethical considerations in HIV cure research: points to consider , 2013, Current opinion in HIV and AIDS.

[5]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[6]  M. Egger,et al.  Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis , 2012, AIDS.

[7]  M. Hughes,et al.  Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age , 2012, AIDS.

[8]  W. Borkowsky,et al.  Increased Gut Microbial Translocation in HIV-infected Children Persists in Virologic Responders and Virologic Failures After Antiretroviral Therapy , 2012, The Pediatric infectious disease journal.

[9]  A. Perelson,et al.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection , 2012, Proceedings of the National Academy of Sciences.

[10]  Jerome H. Kim,et al.  Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection , 2012, PloS one.

[11]  P. Goulder,et al.  Factors influencing T cell activation and programmed death 1 expression in HIV-infected children. , 2011, AIDS research and human retroviruses.

[12]  K. Ruxrungtham,et al.  Immunogenicity assay validation for an HIV vaccine trial: high IFNγ+/IL-2+ CD8+ T cells background in healthy Thais. , 2011, Vaccine.

[13]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[14]  R. Carr-Hill,et al.  Breaking down the wall of silence around children affected by AIDS in Thailand to support their psychosocial health , 2010, AIDS care.

[15]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[16]  John O. Woods,et al.  Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy , 2009, Journal of Virology.

[17]  James A McIntyre,et al.  Early antiretroviral therapy and mortality among HIV-infected infants. , 2008, The New England journal of medicine.

[18]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[19]  G. Ferrari,et al.  Acute HIV infection: the impact of anti‐retroviral treatment on cellular immune responses , 2007, Clinical and experimental immunology.

[20]  S. Gange,et al.  Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. , 2007, AIDS research and human retroviruses.

[21]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[22]  C. Rouzioux,et al.  The frequency of HIV-specific interferon- gamma -producing CD8 T cells is associated with both age and level of antigenic stimulation in HIV-1-infected children. , 2005, The Journal of infectious diseases.

[23]  Thomas C. Quinn,et al.  Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads , 2004, Journal of Virology.

[24]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[25]  S. Furlan,et al.  HIV-Specific CD8+ T Cell Function in Children with Vertically Acquired HIV-1 Infection Is Critically Influenced by Age and the State of the CD4+ T Cell Compartment1 , 2003, The Journal of Immunology.

[26]  R. Yogev,et al.  Infrequent Detection of HIV-1-Specific, But Not Cytomegalovirus-Specific, CD8+ T Cell Responses in Young HIV-1-Infected Infants1 , 2001, The Journal of Immunology.